Medicines and Healthcare products Regulatory Agency

MANUFACTURER'S AUTHORISATION

1: Authorisation Number UK MIA(IMP) 16209 2: Name of authorisation holder MEDIMMUNE LIMITED

MEDIMMUNE LTD (PART OF THE ASTRAZENECA GROUP), AARON 3: Address(es) of manufacturing site(s)

KLUG BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE,

CB21 6ET, UNITED KINGDOM

MEDIMMUNE LIMITED, 1 FRANCIS CRICK AVENUE, CAMBRIDGE 4: Legally registered address of authorisation holder

BIOMEDICAL CAMPUS, CAMBRIDGE, CB2 0AA, UNITED KINGDOM

5: Scope of authorisation and dosage forms ANNEX 1 and/ or ANNEX 2

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 6: Legal Basis of authorisation

2004 [SI 2004/1031]

7: Name of responsible officer of the competent authority

of the member state granting the manufacturing Confidential

authorisation

8: Authorisation Date 27/01/2025

9: Annexes attached Annex 1 and/or Annex 2

SCOPE OF AUTHORISATION

Annex 2

Name and address of the site:

MEDIMMUNE LTD (PART OF THE ASTRAZENECA GROUP), AARON KLUG BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, CB21 6ET, UNITED KINGDOM

Human Investigational Medicinal Products

Authorised Operations

MANUFACTURING OPERATIONS (according to part 1)

IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)

Part 1 - MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.3] Batch certification

[1.2] Non-sterile investigational medicinal products

[1.2.2] Batch certification

[1.3] Biological investigational medicinal products

[1.3.2] Batch certification

Issue Date: 27 Jan 2025

[1.3.2.2] Immunological products [1.3.2.3] Cell therapy products [1.3.2.4] Gene therapy products [1.3.2.5] Biotechnology products [1.3.2.8] Other biological medicinal products Biological active starting materials (when required by national legislation) Part 2 - IMPORTATION OF MEDICINAL PRODUCTS [2.2] Batch certification of imported medicinal products [2.2.1] Sterile Products [2.2.1.1] Aseptically prepared [2.2.1.2] Terminally sterilised [2.2.2] Non-sterile products [2.2.3] Biological medicinal products [2.2.3.2] Immunological products [2.2.3.3] Cell therapy products [2.2.3.4] Gene therapy products [2.2.3.5] Biotechnology products [2.2.3.8] Other biological medicinal products

[2.3] Other Importation Activities

[2.3.2] Importation of Intermediate which undergoes further processing

Biological active starting materials (when required by national legislation)

[2.3.4] Other

Importation of QP certified IMPs from a country on the approved country for import list



Issue Date: 27 Jan 2025